B細胞はサルコマの生存と免疫療法反応と関連しています
Florent Petitprez1,2,3,4, Aurélien de Reyniès4, Emily Z Keung5
1Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.
Nature
|January 17, 2020
まとめ
研究者は軟組織サルコマの腫瘍を5つの免疫現象型に分類した. クラスEの腫瘍におけるB細胞に富んだ三次リンパ性構造は,PD1阻害療法に対するよりよい生存率と反応を示しています.
科学分野:
- 腫瘍学
- 免疫学
- 癌 研究
背景:
- 軟組織サルコマ (STS) は50種類以上の多種多様ながん群である.
- 免疫チェックポイントの阻害を含む臨床表現と治療反応は,STSサブタイプによって著しく異なります.
研究 の 目的:
- 608 STS腫瘍の遺伝子発現プロフィールを調査し,臨床的変異性を理解する.
- 腫瘍の微小環境の組成に基づいてSTSの免疫ベースの分類を確立する.
主な方法:
- 608種類の軟組織サルコマの遺伝子発現プロフィールの分析
- 免疫フェノタイプを特徴づけるために,独立した検証コホートにおける in situ 分析.
- 2期臨床試験におけるPD1阻害 (ペムブロリズマブ) に対する反応の評価
主要な成果:
- 免疫機能が低い (A,B),免疫力が高い (D,E),および高度に血管化された (C) の5つの異なる免疫フェノタイプを特定した.
- クラスEの腫瘍は,B細胞,T細胞,および卵泡の dendritic細胞に富んだ三次リンパ性構造を示します.
- B細胞は最強の予後因子であり,Eクラスでは生存率が向上し,ペンブロリズマブに対する反応が高かった.
結論:
- 軟組織肉腫の患者で 明確な免疫サブタイプが確認されました
- B細胞に富んだ三次リンパ球構造は,治療反応を予測し,臨床決定を導くための潜在的なバイオマーカーです.
- この発見は,他の免疫関連疾患にもより広範な影響を及ぼす可能性があります.
さらに関連する動画
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
1.6K
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
1.3K
関連する概念動画
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
B Cell Activation and Differentiation
15.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cytotoxic T Cells-mediated Immune Response
6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
